CompanyKLRSNasdaqBerkeley Heights, NJ

Kalaris Therapeutics, Inc.

Kalaris Therapeutics is a clinical-stage biopharmaceutical company developing treatments for retinal diseases.

SEC EDGAR ClinicalTrials.gov kalaristx.com

S-1Aug 28Latest SEC filing

Aug 11Latest story

August 2026

Kalaris reports Q2 2026 results, dosing continues in TH103 mid-stage trial

Aug 11Quarterly updateKalaris Therapeutics, Inc.

July 2026

Kalaris Therapeutics names Liisa Bayko as chief financial officer

Jul 20PeopleKalaris Therapeutics, Inc.

Kalaris reports expanded Phase 1a data for TH103 in wet AMD

Jul 17Clinical readoutKalaris Therapeutics, Inc.

Kalaris Therapeutics board director resigns, new director elected

Jul 6PeopleKalaris Therapeutics, Inc.